PCRX Pacira Pharmaceuticals Inc.

37.20
+0.75  (2%)
Previous Close 36.45
Open 36.45
Price To book 5.75
Market Cap 1500705660
Shares 40,341,550
Volume 373,604
Short Ratio 7.76
Av. Daily Volume 763,699

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved October 31, 2011.
EXPAREL
Postsurgical pain
Phase 3 data released July 25, 2017. Upper extremity met primary endpoint, lower extremity trial missed endpoint. sNDA filing due later in 2017.
EXPAREL
Single-dose injection femoral nerve block for total knee arthroplasty surgery

Latest News

  1. Pacira Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
  2. See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc.
  3. Pacira Pharmaceuticals, Aetna, and the American Association of Oral and Maxillofacial Surgeons Join Together in a Program to Reduce Opioid Exposure for Patients Undergoing Wisdom Tooth Extraction
  4. Pacira Pharmaceuticals Announces Multiple EXPAREL Data Presentations at the Upcoming New York School of Regional Anesthesia Annual Fall Symposium
  5. Pacira Pharmaceuticals to Present at the 2017 H.C. Wainwright 19th Annual Global Investment Conference
  6. Pacira Pharmaceuticals to Present at the 2017 Wells Fargo Healthcare Conference
  7. Steven Cohen Plunges Into Opioid Replacement Maker Pacira
  8. Pacira Pharmaceuticals Focuses on Exparel's Label Expansion
  9. Edited Transcript of PCRX earnings conference call or presentation 2-Aug-17 12:30pm GMT
  10. [$$] Maverick Therapeutics Taps Former Pacira Executive as CEO
  11. Pacira Pharmaceuticals to Present at the 2017 Wedbush Pacgrow Healthcare Conference
  12. Pacira Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PCRX) : August 7, 2017
  13. Pacira (PCRX) Q2 Loss Wider than Expected, Revenues Miss
  14. Pacira reports 2Q loss
  15. Pacira Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results
  16. Investor Network: Pacira Pharmaceuticals, Inc. to Host Earnings Call
  17. ETFs with exposure to Pacira Pharmaceuticals, Inc. : July 27, 2017
  18. Pacira Pharmaceuticals Inc (PCRX) and EXACT Sciences Corporation (EXAS) Are Shaking Up the Market